Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Business Update
Pharma company appoints CRO to manage phenoxodiol trial
April 7th, 2005
Marshall Edwards, Inc., (MSHL; MSH) has appointed an international clinical research organization (CRO) to project manage the final stages of the clinical program of the experimental anticancer drug, phenoxodiol. The CRO will manage a new trial that seeks to produce data suitable for an application seeking marketing approval in the U.S. and elsewhere for phenoxodiol for the treatment of recurrent, chemo-refractory ovarian cancer. This pivotal trial will be known as the OVATURE trial. "This pivotal study has been expedited in a departure from the normal progression of clinical development, as a result of the findings from the...
Source: Women's Health Weekly (2005-04-07)
|
